Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus.
Journal
Nature reviews. Endocrinology
ISSN: 1759-5037
Titre abrégé: Nat Rev Endocrinol
Pays: England
ID NLM: 101500078
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
28
04
2022
pubmed:
2
6
2022
medline:
16
7
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Enteroviruses are believed to trigger or accelerate islet autoimmunity in genetically susceptible individuals, thereby resulting in loss of functional insulin-producing β-cells and type 1 diabetes mellitus (T1DM). Although enteroviruses are primarily involved in acute and lytic infections in vitro and in vivo, they can also establish a persistent infection. Prospective epidemiological studies have strongly associated the persistence of enteroviruses, especially coxsackievirus B (CVB), with the appearance of islet autoantibodies and an increased risk of T1DM. CVB can persist in pancreatic ductal and β-cells, which leads to structural or functional alterations of these cells, and to a chronic inflammatory response that promotes recruitment and activation of pre-existing autoreactive T cells and β-cell autoimmune destruction. CVB persistence in other sites, such as the intestine, blood cells and thymus, has been described; these sites could serve as a reservoir for infection or reinfection of the pancreas, and this persistence could have a role in the disturbance of tolerance to β-cells. This Review addresses the involvement of persistent enterovirus infection in triggering islet autoimmunity and T1DM, as well as current strategies to control enterovirus infections for preventing or reducing the risk of T1DM onset.
Identifiants
pubmed: 35650334
doi: 10.1038/s41574-022-00688-1
pii: 10.1038/s41574-022-00688-1
pmc: PMC9157043
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-516Informations de copyright
© 2022. Springer Nature Limited.
Références
Noble, J. A. Immunogenetics of type 1 diabetes: a comprehensive review. J. Autoimmun. 64, 101–112 (2015).
pubmed: 26272854
doi: 10.1016/j.jaut.2015.07.014
Ilonen, J., Lempainen, J. & Veijola, R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 15, 635–650 (2019).
pubmed: 31534209
doi: 10.1038/s41574-019-0254-y
Geravandi, S., Liu, H. & Maedler, K. Enteroviruses and T1D: is it the virus, the genes or both which cause T1D. Microorganisms 8, 1017 (2020).
pmcid: 7409303
doi: 10.3390/microorganisms8071017
Sharp, S. A. et al. Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care 42, 200–207 (2019).
pubmed: 30655379
pmcid: 6341291
doi: 10.2337/dc18-1785
Qu, H. Q. et al. Improved genetic risk scoring algorithm for type 1 diabetes prediction. Pediatr. Diabetes 23, 320–323 (2022).
pubmed: 34997821
doi: 10.1111/pedi.13310
Patterson, C. C. et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107842 (2019).
pubmed: 31518658
doi: 10.1016/j.diabres.2019.107842
Redondo, M. J., Jeffrey, J., Fain, P. R., Eisenbarth, G. S. & Orban, T. Concordance for islet autoimmunity among monozygotic twins. N. Engl. J. Med. 359, 2849–2850 (2008).
pubmed: 19109586
doi: 10.1056/NEJMc0805398
Tuomilehto, J., Ogle, G. D., Lund-Blix, N. A. & Stene, L. C. Update on worldwide trends in occurrence of childhood type 1 diabetes in 2020. Pediatr. Endocrinol. Rev. 17, 198–209 (2020).
pubmed: 32208564
Fathallah, N., Slim, R., Larif, S., Hmouda, H. & Ben Salem, C. Drug-induced hyperglycaemia and diabetes. Drug Saf. 38, 1153–1168 (2015).
pubmed: 26370106
doi: 10.1007/s40264-015-0339-z
Fève, B. & Scheen, A. J. When therapeutic drugs lead to diabetes. Diabetologia 65, 751–762 (2022).
pubmed: 35244742
doi: 10.1007/s00125-022-05666-w
Hober, D. & Sauter, P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 6, 279–289 (2010). The interplay between enterovirus infections and β-cells, the immune system and host genes in the pathogenesis of T1DM is discussed.
pubmed: 20351698
doi: 10.1038/nrendo.2010.27
Rewers, M. & Ludvigsson, J. Environmental risk factors for type 1 diabetes. Lancet 387, 2340–2348 (2016).
pubmed: 27302273
pmcid: 5571740
doi: 10.1016/S0140-6736(16)30507-4
Yoon, J. W. & Jun, H. S. Viruses cause type 1 diabetes in animals. Ann. N. Y. Acad. Sci. 1079, 138–146 (2006).
pubmed: 17130545
doi: 10.1196/annals.1375.021
Jaïdane, H. et al. Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. Diabetes/Metab. Res. Rev. 25, 591–603 (2009).
doi: 10.1002/dmrr.995
Jaïdane, H. et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: enterovirus, thymus and type 1 diabetes pathogenesis. Clin. Exp. Immunol. 168, 39–46 (2012).
pubmed: 22385235
pmcid: 3390491
doi: 10.1111/j.1365-2249.2011.04558.x
Yeung, W.-C. G., Rawlinson, W. D. & Craig, M. E. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342, d35 (2011).
pubmed: 21292721
pmcid: 3033438
doi: 10.1136/bmj.d35
Hober, D. & Sane, F. Enteroviral pathogenesis of type 1 diabetes. Discov. Med. 10, 151–160 (2010).
pubmed: 20807476
Allen, D. W., Kim, K. W., Rawlinson, W. D. & Craig, M. E. Maternal virus infections in pregnancy and type 1 diabetes in their offspring: systematic review and meta-analysis of observational studies. Rev. Med. Virol. 28, e1974 (2018).
pubmed: 29569297
doi: 10.1002/rmv.1974
Laitinen, O. H. et al. Coxsackievirus B1 is associated with induction of β-cells autoimmunity that portends type 1 diabetes. Diabetes 63, 446–455 (2014).
pubmed: 23974921
doi: 10.2337/db13-0619
Oikarinen, S. et al. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes 63, 655–662 (2014). Study confirming that CVB1 is the only coxsackievirus group B serotype showing association with T1DM risk in five European countries.
pubmed: 24009257
doi: 10.2337/db13-0620
Ifie, E. et al. Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia 61, 2344–2355 (2018). A specific isoform of the CAR has been found to be abundant in human β-cells and is localized mainly in insulin secretory granules, which might contribute to the susceptibility of human β-cells to enteroviral infection.
pubmed: 30074059
pmcid: 6182664
doi: 10.1007/s00125-018-4704-1
Isaacs, S. R. et al. Viruses and type 1 diabetes: from enteroviruses to the virome. Microorganisms 9, 1519 (2021).
pubmed: 34361954
pmcid: 8306446
doi: 10.3390/microorganisms9071519
Chehadeh, W. et al. Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in β cells. J. Virol. 74, 10153–10164 (2000). This study provided the basis of the evidence for persistent infection of primary human pancreatic islets with CVB in culture.
pubmed: 11024144
pmcid: 102054
doi: 10.1128/JVI.74.21.10153-10164.2000
Brilot, F. et al. Persistent infection of human thymic epithelial cells by coxsackievirus B4. J. Virol. 76, 5260–5265 (2002).
pubmed: 11967339
pmcid: 136150
doi: 10.1128/JVI.76.10.5260-5265.2002
Jaidane, H. et al. Persistent infection of thymic epithelial cells with coxsackievirus B4 results in decreased expression of type 2 insulin-like growth factor. J. Virol. 86, 11151–11162 (2012).
pubmed: 22855493
pmcid: 3457166
doi: 10.1128/JVI.00726-12
Sane, F. et al. Coxsackievirus B4 can infect human pancreas ductal cells and persist in ductal-like cell cultures which results in inhibition of Pdx1 expression and disturbed formation of islet-like cell aggregates. Cell. Mol. Life Sci. 70, 4169–4180 (2013).
pubmed: 23775130
doi: 10.1007/s00018-013-1383-4
Nekoua, M. P. et al. Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity. Cell. Mol. Life Sci. 77, 179–194 (2020).
pubmed: 31172216
doi: 10.1007/s00018-019-03168-4
Nekoua, M. P. et al. Persistence of coxsackievirus B4 in pancreatic β cells disturbs insulin maturation, pattern of cellular proteins, and DNA methylation. Microorganisms 9, 1125 (2021).
pubmed: 34067388
pmcid: 8224704
doi: 10.3390/microorganisms9061125
See, D. M. & Tilles, J. G. Pathogenesis of virus-induced diabetes in mice. J. Infect. Dis. 171, 1131–1138 (1995).
pubmed: 7751687
doi: 10.1093/infdis/171.5.1131
Richardson, S. J., Willcox, A., Bone, A. J., Foulis, A. K. & Morgan, N. G. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52, 1143–1151 (2009).
pubmed: 19266182
doi: 10.1007/s00125-009-1276-0
Richardson, S. J., Leete, P., Bone, A. J., Foulis, A. K. & Morgan, N. G. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia 56, 185–193 (2013).
pubmed: 23064357
doi: 10.1007/s00125-012-2745-4
Krogvold, L. et al. Detection of a low-grade enteroviral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64, 1682–1687 (2015). The Diabetes Virus Detection study (DiViD) is the first study confirming the presence of enterovirus in pancreatic islets of living patients with newly diagnosed T1DM using enterovirus-specific real-time PCR.
pubmed: 25422108
doi: 10.2337/db14-1370
Morgan, N. G. & Richardson, S. J. Enteroviruses as causative agents in type 1 diabetes: loose ends or lost cause? Trends Endocrinol. Metab. 25, 611–619 (2014).
pubmed: 25175301
doi: 10.1016/j.tem.2014.08.002
De Beeck, A. O. & Eizirik, D. L. Viral infections in type 1 diabetes mellitus–why the β cells? Nat. Rev. Endocrinol. 12, 263–273 (2016).
pmcid: 5348720
doi: 10.1038/nrendo.2016.30
Honkanen, H. et al. Detection of enteroviruses in stools precedes islet autoimmunity by several months: possible evidence for slowly operating mechanisms in virus-induced autoimmunity. Diabetologia 60, 424–431 (2017).
pubmed: 28070615
doi: 10.1007/s00125-016-4177-z
Kim, K. W. et al. Higher abundance of enterovirus A species in the gut of children with islet autoimmunity. Sci. Rep. 9, 1749 (2019).
pubmed: 30741981
pmcid: 6370883
doi: 10.1038/s41598-018-38368-8
Oikarinen, S. et al. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64, 2491–2501 (2021).
pubmed: 34390364
pmcid: 8494699
doi: 10.1007/s00125-021-05525-0
Vehik, K. et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat. Med. 25, 1865–1872 (2019). Gut virome analysis of young children at increased genetic risk of T1DM revealed that long-term shedding of the same enterovirus serotype as CVB in the stool is strongly associated with the development of islet autoimmunity.
pubmed: 31792456
pmcid: 6898786
doi: 10.1038/s41591-019-0667-0
Jaïdane, H. et al. Enteroviruses and type 1 diabetes: towards a better understanding of the relationship. Rev. Med. Virol. 20, 265–280 (2010).
pubmed: 20629044
doi: 10.1002/rmv.647
Hober, D. & Alidjinou, E. K. Enteroviral pathogenesis of type 1 diabetes: queries and answers. Curr. Opin. Infect. Dis. 26, 263–269 (2013).
pubmed: 23549392
doi: 10.1097/QCO.0b013e3283608300
Alhazmi, A. et al. Enteroviruses and type 1 diabetes mellitus: an overlooked relationship in some regions. Microorganisms 8, 1458 (2020).
pmcid: 7598226
doi: 10.3390/microorganisms8101458
Wang, K. et al. Association between enterovirus infection and type 1 diabetes risk: a meta-analysis of 38 case-control studies. Front. Endocrinol. 12, 706964 (2021). The most recent meta-analysis of studies (encompassing 5,921 individuals) on the association between enterovirus infections and T1DM.
doi: 10.3389/fendo.2021.706964
Kobayashi, T., Nishida, Y., Tanaka, S. & Aida, K. Pathological changes in the pancreas of fulminant type 1 diabetes and slowly progressive insulin-dependent diabetes mellitus (SPIDDM): innate immunity in fulminant type 1 diabetes and SPIDDM. Diabetes Metab. Res. Rev. 27, 965–970 (2011).
pubmed: 22069294
doi: 10.1002/dmrr.1237
Tanaka, S., Aida, K., Nishida, Y. & Kobayashi, T. Pathophysiological mechanisms involving aggressive islet cell destruction in fulminant type 1 diabetes. Endocr. J. 60, 837–845 (2013).
pubmed: 23774118
doi: 10.1507/endocrj.EJ13-0222
Takita, M. et al. Unique inflammatory changes in exocrine and endocrine pancreas in enterovirus-induced fulminant type 1 diabetes. J. Clin. Endocrinol. Metab. 104, 4282–4294 (2019).
pubmed: 31112279
doi: 10.1210/jc.2018-02672
Kobayashi, T., Tanaka, S. & Aida, K. Unique pathological changes in the pancreas of fulminant type 1 diabetes. Diabetol. Int. 11, 323–328 (2020).
pubmed: 33088638
pmcid: 7538509
doi: 10.1007/s13340-020-00462-6
Ylipaasto, P. et al. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 47, 225–239 (2004).
pubmed: 14727023
doi: 10.1007/s00125-003-1297-z
Dotta, F. et al. Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc. Natl Acad. Sci. USA 104, 5115–5120 (2007).
pubmed: 17360338
pmcid: 1829272
doi: 10.1073/pnas.0700442104
Oikarinen, M. et al. Detection of enteroviruses in the intestine of type 1 diabetic patients. Clin. Exp. Immunol. 151, 71–75 (2008).
pubmed: 17991291
pmcid: 2276929
doi: 10.1111/j.1365-2249.2007.03529.x
Oikarinen, M. et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 61, 687–691 (2012).
pubmed: 22315304
pmcid: 3282798
doi: 10.2337/db11-1157
Hyöty, H. Viruses in type 1 diabetes. Pediatr. Diabetes 17, 56–64 (2016).
pubmed: 27411438
doi: 10.1111/pedi.12370
Geravandi, S., Richardson, S., Pugliese, A. & Maedler, K. Localization of enteroviral RNA within the pancreas in donors with T1D and T1D-associated autoantibodies. Cell Rep. Med. 2, 100371 (2021).
pubmed: 34467248
pmcid: 8385321
doi: 10.1016/j.xcrm.2021.100371
Turkki, P. et al. Slow infection due to lowering the amount of intact versus empty particles is a characteristic feature of coxsackievirus B5 dictated by the structural proteins. J. Virol. 93, e01130-19 (2019).
pubmed: 31375587
pmcid: 6798118
doi: 10.1128/JVI.01130-19
Sioofy-Khojine, A. B. et al. Molecular epidemiology of enteroviruses in young children at increased risk of type 1 diabetes. PLoS ONE 13, e0201959 (2018).
pubmed: 30192755
pmcid: 6128458
doi: 10.1371/journal.pone.0201959
Racaniello, V. R. in Fields Virology (eds Knipe, D. M., Howley, P. M.) 453–490 (Lippincott Williams & Wilkins, 2013).
Kiyono, H. & Fukuyama, S. Nalt-versus Peyer’s-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4, 699–710 (2004).
pubmed: 15343369
pmcid: 7097243
doi: 10.1038/nri1439
Badia-Boungou, F. et al. Marker of coxsackievirus-B4 infection in saliva of patients with type 1 diabetes. Diabetes Metab. Res. Rev. 33, e2916 (2017).
doi: 10.1002/dmrr.2916
Nekoua, M. P. et al. Salivary anti-coxsackievirus-B4 neutralizing activity and pattern of immune parameters in patients with type 1 diabetes: a pilot study. Acta Diabetol. 55, 827–834 (2018).
pubmed: 29774468
doi: 10.1007/s00592-018-1158-3
Hyöty, H. et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabetes 44, 652–657 (1995).
pubmed: 7789630
doi: 10.2337/diab.44.6.652
Sadeharju, K. et al. Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial. Clin. Exp. Immunol. 132, 271–277 (2003).
pubmed: 12699416
pmcid: 1808709
doi: 10.1046/j.1365-2249.2003.02147.x
Lonnrot, M. et al. Enterovirus infections as a risk factor for β-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention study. Diabetes 49, 1314–1318 (2000).
pubmed: 10923631
doi: 10.2337/diabetes.49.8.1314
Salminen, K. et al. Enterovirus infections are associated with the induction of β-cell autoimmunity in a prospective birth cohort study. J. Med. Virol. 69, 91–98 (2003).
pubmed: 12436483
doi: 10.1002/jmv.10260
Oikarinen, S. et al. Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 60, 276–279 (2011).
pubmed: 20943747
doi: 10.2337/db10-0186
Sioofy-Khojine, A. B. et al. Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 61, 1193–1202 (2018).
pubmed: 29404673
doi: 10.1007/s00125-018-4561-y
Chehadeh, W. et al. Increased level of interferon-α in blood of patients with insulin- dependent diabetes mellitus: relationship with coxsackievirus B infection. J. Infect. Dis. 181, 1929–1939 (2000).
pubmed: 10837172
doi: 10.1086/315516
Salvatoni, A. et al. Intrafamilial spread of enterovirus infections at the clinical onset of type 1 diabetes. Pediatr. Diabetes 14, 407–416 (2013).
pubmed: 23763622
doi: 10.1111/pedi.12056
Schulte, B. M. et al. Detection of enterovirus RNA in peripheral blood mononuclear cells of type 1 diabetic patients beyond the stage of acute infection. Viral Immunol. 23, 99–104 (2010).
pubmed: 20121407
doi: 10.1089/vim.2009.0072
Yin, H., Berg, A. K., Tuvemo, T. & Frisk, G. Enterovirus RNA is found in peripheral blood mononuclear cells in a majority of type 1 diabetic children at onset. Diabetes 51, 1964–1971 (2002).
pubmed: 12031987
doi: 10.2337/diabetes.51.6.1964
Alidjinou, E. K. et al. Monocytes of patients with type 1 diabetes harbour enterovirus RNA. Eur. J. Clin. Invest. 45, 918–924 (2015).
pubmed: 26108863
doi: 10.1111/eci.12485
Kramná, L. et al. Gut virome sequencing in children with early islet autoimmunity. Diabetes Care 38, 930–933 (2015).
pubmed: 25678103
doi: 10.2337/dc14-2490
Mercalli, A. et al. No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 55, 2479–2488 (2012).
pubmed: 22684312
doi: 10.1007/s00125-012-2591-4
Lee, H. S. et al. Next-generation sequencing for viruses in children with rapid-onset type 1 diabetes. Diabetologia 56, 1705–1711 (2013).
pubmed: 23657799
pmcid: 4019381
doi: 10.1007/s00125-013-2924-y
Zhao, G. et al. Intestinal virome changes precede autoimmunity in type I diabetes-susceptible children. Proc. Natl Acad. Sci. USA 114, E6166–E6175 (2017).
pubmed: 28696303
pmcid: 5544325
doi: 10.1073/pnas.1706359114
Cinek, O. et al. Eukaryotic viruses in the fecal virome at the onset of type 1 diabetes: a study from four geographically distant African and Asian countries. Pediatr. Diabetes 22, 558–566 (2021).
pubmed: 33786936
doi: 10.1111/pedi.13207
Conaldi, P. G. et al. Persistent infection of human vascular endothelial cells by group B coxsackieviruses. J. Infect. Dis. 175, 693–696 (1997).
pubmed: 9041346
doi: 10.1093/infdis/175.3.693
Frisk, G. Mechanisms of chronic enteroviral persistence in tissue. Curr. Opin. Infect. Dis. 14, 251–256 (2001).
pubmed: 11964840
doi: 10.1097/00001432-200106000-00002
Pinkert, S. et al. Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line. J. Virol. 85, 13409–13419 (2011).
pubmed: 21976640
pmcid: 3233118
doi: 10.1128/JVI.00621-11
Klingel, K. et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl Acad. Sci. USA 89, 314–318 (1992).
pubmed: 1309611
pmcid: 48227
doi: 10.1073/pnas.89.1.314
Chapman, N. M. & Kim, K. S. Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr. Top. Microbiol. Immunol. 323, 275–292 (2008).
pubmed: 18357775
Cunningham, L., Bowles, N. E., Lane, R. J. M., Dubowitz, V. & Archard, L. C. Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J. Gen. Virol. 71, 1399–1402 (1990).
pubmed: 2161907
doi: 10.1099/0022-1317-71-6-1399
Chia, J. K. S. The role of enterovirus in chronic fatigue syndrome. J. Clin. Pathol. 58, 1126–1132 (2005).
pubmed: 16254097
pmcid: 1770761
doi: 10.1136/jcp.2004.020255
Frisk, G. & Tuvemo, T. Enterovirus infections with β-cell tropic strains are frequent in siblings of children diagnosed with type 1 diabetes children and in association with elevated levels of GAD65 antibodies. J. Med. Virol. 73, 450–459 (2004).
pubmed: 15170642
doi: 10.1002/jmv.20111
Anagandula, M. et al. Infection of human islets of Langerhans with two strains of coxsackie B virus serotype 1: assessment of virus replication, degree of cell death and induction of genes involved in the innate immunity pathway. J. Med. Virol. 86, 1402–1411 (2014).
pubmed: 24249667
doi: 10.1002/jmv.23835
Marroqui, L. et al. Differential cell autonomous responses determine the outcome of coxsackievirus infections in murine pancreatic α and β cells. Elife 4, e06990 (2015).
pubmed: 26061776
pmcid: 4480275
doi: 10.7554/eLife.06990
Roivainen, M. et al. Mechanisms of coxsackievirus-induced damage to human pancreatic β-cells. J. Clin. Endocrinol. Metab. 85, 432–440 (2000).
pubmed: 10634421
Oikarinen, M. et al. Analysis of pancreas tissue in a child positive for islet cell antibodies. Diabetologia 51, 1796–1802 (2008).
pubmed: 18696046
doi: 10.1007/s00125-008-1107-8
Spagnuolo, I., Patti, A., Sebastiani, G., Nigi, L. & Dotta, F. The case for virus-induced type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 20, 292–298 (2013).
pubmed: 23743646
doi: 10.1097/MED.0b013e328362a7d7
Knoch, K. P. et al. PTBP1 is required for glucose-stimulated cap-independent translation of insulin granule proteins and Coxsackieviruses in beta cells. Mol. Metab. 3, 518–530 (2014).
pubmed: 25061557
pmcid: 4099505
doi: 10.1016/j.molmet.2014.05.002
Hodik, M. et al. Enterovirus infection of human islets of Langerhans affects β-cell function resulting in disintegrated islets, decreased glucose stimulated insulin secretion and loss of Golgi structure. BMJ Open Diabetes Res. Care 4, e000179 (2016).
pubmed: 27547409
pmcid: 4985798
doi: 10.1136/bmjdrc-2015-000179
Nyalwidhe, J. O. et al. Coxsackievirus-induced proteomic alterations in primary human islets provide insights for the etiology of diabetes. J. Endocr. Soc. 1, 1272–1286 (2017).
pubmed: 29264452
pmcid: 5686651
doi: 10.1210/js.2017-00278
Yoon, J. W., Austin, M., Onodera, T. & Notkins, A. L. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N. Engl. J. Med. 300, 1173–1179 (1979).
pubmed: 219345
doi: 10.1056/NEJM197905243002102
Yin, H., Berg, A.-K., Westman, J., Hellerström, C. & Frisk, G. Complete nucleotide sequence of a coxsackievirus B-4 strain capable of establishing persistent infection in human pancreatic islet cells: effects on insulin release, proinsulin synthesis, and cell morphology. J. Med. Virol. 68, 544–557 (2002).
pubmed: 12376963
doi: 10.1002/jmv.10236
Alidjinou, E. K. et al. Persistence of coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes. Virulence 8, 1229–1244 (2017).
pubmed: 28112573
pmcid: 5711397
doi: 10.1080/21505594.2017.1284735
Lietzén, N. et al. Coxsackievirus B persistence modifies the proteome and the secretome of pancreatic ductal cells. iScience 19, 340–357 (2019).
pubmed: 31404834
pmcid: 6699423
doi: 10.1016/j.isci.2019.07.040
Owusu, I. A., Quaye, O., Passalacqua, K. D. & Wobus, C. E. Egress of non-enveloped enteric RNA viruses. J. Gen. Virol. 102, 001557 (2021).
pmcid: 8515858
doi: 10.1099/jgv.0.001557
Netanyah, E. et al. Extracellular vesicles released by enterovirus-infected EndoC-βH1 cells mediate non-lytic viral spread. Microorganisms 8, 1753 (2020).
pmcid: 7695210
doi: 10.3390/microorganisms8111753
Chen, Y. H. et al. Phosphatidylserine vesicles enable efficient en bloc transmission of enteroviruses. Cell 160, 619–630 (2015).
pubmed: 25679758
pmcid: 6704014
doi: 10.1016/j.cell.2015.01.032
Busse, N. et al. Detection and localization of viral infection in the pancreas of patients with type 1 diabetes using short fluorescently-labelled oligonucleotide probes. Oncotarget 8, 12620–12636 (2017).
pubmed: 28147344
pmcid: 5355040
doi: 10.18632/oncotarget.14896
Bertin, A. et al. Coxsackievirus-B4 infection of human primary pancreatic ductal cell cultures results in impairment of differentiation into insulin-producing cells. Viruses 11, 597 (2019).
pmcid: 6669621
doi: 10.3390/v11070597
Lysy, P. A., Weir, G. C. & Bonner-Weir, S. Making β cells from adult cells within the pancreas. Curr. Diab. Rep. 13, 695–703 (2013).
pubmed: 23925431
pmcid: 3798031
doi: 10.1007/s11892-013-0400-1
Isaacs, S. R. et al. MicroRNAs in type 1 diabetes: complex interregulation of the immune system, β cell function and viral infections. Curr. Diabetes Rep. 16, 133 (2016).
doi: 10.1007/s11892-016-0819-2
Engelmann, I., Alidjinou, E. K., Bertin, A., Sane, F. & Hober, D. miRNAs in enterovirus infection. Crit. Rev. Microbiol. 44, 701–714 (2018).
pubmed: 30106324
doi: 10.1080/1040841X.2018.1499608
Engelmann, I. et al. Persistent coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic cells. Cell. Mol. Life Sci. 74, 3851–3861 (2017).
pubmed: 28601984
doi: 10.1007/s00018-017-2567-0
Kim, K. W. et al. Coxsackievirus B5 infection induces dysregulation of microRNAs predicted to target known type 1 diabetes risk genes in human pancreatic islets. Diabetes 65, 996–1003 (2016).
pubmed: 26558682
doi: 10.2337/db15-0956
Deitz, S. B., Dodd, D. A., Cooper, S., Parham, P. & Kirkegaard, K. MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A. Proc. Natl Acad. Sci. USA 97, 13790–13795 (2000).
pubmed: 11095746
pmcid: 17654
doi: 10.1073/pnas.250483097
Moffat, K. et al. Effects of foot-and-mouth disease virus nonstructural proteins on the structure and function of the early secretory pathway: 2BC but not 3A blocks endoplasmic reticulum-to-Golgi transport. J. Virol. 79, 4382–4395 (2005).
pubmed: 15767438
pmcid: 1061540
doi: 10.1128/JVI.79.7.4382-4395.2005
de Jong, A. S. et al. The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi. J. Biol. Chem. 281, 14144–14150 (2006).
pubmed: 16540472
doi: 10.1074/jbc.M511766200
Cornell, C. T., Kiosses, W. B., Harkins, S. & Whitton, J. L. Inhibition of protein trafficking by coxsackievirus B3: multiple viral proteins target a single organelle. J. Virol. 80, 6637–6647 (2006).
pubmed: 16775351
pmcid: 1488957
doi: 10.1128/JVI.02572-05
Cornell, C. T., Kiosses, W. B., Harkins, S. & Whitton, J. L. Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J. Virol. 81, 6785–6797 (2007).
pubmed: 17442717
pmcid: 1933326
doi: 10.1128/JVI.00198-07
Chaffey, J. R. et al. Investigation of the utility of the 1.1B4 cell as a model human beta cell line for study of persistent enteroviral infection. Sci. Rep. 11, 15624 (2021).
pubmed: 34341375
pmcid: 8329048
doi: 10.1038/s41598-021-94878-y
Brusko, T. M., Wasserfall, C. H., Clare-Salzler, M. J., Schatz, D. A. & Atkinson, M. A. Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes 54, 1407–1414 (2005).
pubmed: 15855327
doi: 10.2337/diabetes.54.5.1407
Walker, L. S. K. & von Herrath, M. CD4 T cell differentiation in type 1 diabetes. Clin. Exp. Immunol. 183, 16–29 (2016).
pubmed: 26102289
doi: 10.1111/cei.12672
Michaux, H. et al. How does thymus infection by coxsackievirus contribute to the pathogenesis of type 1 diabetes? Front. Immunol. 6, 338 (2015).
pubmed: 26175734
pmcid: 4485212
doi: 10.3389/fimmu.2015.00338
Reetoo, K. N. et al. Quantitative analysis of viral RNA kinetics in coxsackievirus B3-induced murine myocarditis: biphasic pattern of clearance following acute infection, with persistence of residual viral RNA throughout and beyond the inflammatory phase of disease. J. Gen. Virol. 81, 2755–2762 (2000).
pubmed: 11038389
doi: 10.1099/0022-1317-81-11-2755
Kim, K.-S. et al. 5′-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J. Virol. 79, 7024–7041 (2005).
pubmed: 15890942
pmcid: 1112132
doi: 10.1128/JVI.79.11.7024-7041.2005
Chapman, N. M., Kim, K.-S., Drescher, K. M., Oka, K. & Tracy, S. 5′ terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 375, 480–491 (2008).
pubmed: 18378272
doi: 10.1016/j.virol.2008.02.030
Tracy, S., Smithee, S., Alhazmi, A. & Chapman, N. Coxsackievirus can persist in murine pancreas by deletion of 5′ terminal genomic sequences. J. Med. Virol. 87, 240–247 (2015).
pubmed: 25111164
doi: 10.1002/jmv.24039
Jaïdane, H. et al. Prolonged viral RNA detection in blood and lymphoid tissues from coxsackievirus B4 E2 orally-inoculated Swiss mice. Microbiol. Immunol. 50, 971–974 (2006).
pubmed: 17179665
doi: 10.1111/j.1348-0421.2006.tb03874.x
Michaux, H. et al. Modulation of IGF2 expression in the murine thymus and thymic epithelial cells following coxsackievirus-B4 infection. Microorganisms 9, 402 (2021).
pubmed: 33672010
pmcid: 7919294
doi: 10.3390/microorganisms9020402
Kecha-Kamoun, O., Achour, I. & Martens, H. Thymic expression of insulin-related genes in an animal model of autoimmune type 1 diabetes. Diabetes Metab. Res. Rev. 17, 146–152 (2001).
pubmed: 11307180
doi: 10.1002/dmrr.182
Alhazmi, A. et al. Effect of coxsackievirus B4 infection on the thymus: elucidating its role in the pathogenesis of type 1 diabetes. Microorganisms 9, 1177 (2021).
pubmed: 34072590
pmcid: 8229779
doi: 10.3390/microorganisms9061177
Euscher, E., Davis, J., Holzman, I. & Nuovo, G. J. Coxsackie virus infection of the placenta associated with neurodevelopmental delays in the newborn. Obstet. Gynecol. 98, 1019–1026 (2001).
pubmed: 11755547
Abzug, M. J. Presentation, diagnosis, and management of enterovirus infections in neonates. Pediatr. Drugs 6, 1–10 (2004).
doi: 10.2165/00148581-200406010-00001
Satosar, A., Ramirez, N. C., Bartholomew, D., Davis, J. & Nuovo, G. J. Histologic correlates of viral and bacterial infection of the placenta associated with severe morbidity and mortality in the newborn. Hum. Pathol. 35, 536–545 (2004).
pubmed: 15138926
doi: 10.1016/j.humpath.2004.01.015
Jaïdane, H. et al. In-utero coxsackievirus B4 infection of the mouse thymus. Clin. Exp. Immunol. 187, 399–407 (2017).
pubmed: 27790717
doi: 10.1111/cei.12893
Halouani, A. et al. Assessment of thymic output dynamics after in utero infection of mice with coxsackievirus B4. Front. Immunol. 11, 481 (2020).
pubmed: 32300341
pmcid: 7142265
doi: 10.3389/fimmu.2020.00481
Halouani, A. et al. Coxsackievirus B4 transplacental infection severely disturbs central tolerogenic mechanisms in the fetal thymus. Microorganisms 9, 1537 (2021).
pubmed: 34361972
pmcid: 8303261
doi: 10.3390/microorganisms9071537
Geenen, V. & Hober, D. For debate: programing of the autoimmune diabetogenic response in the thymus during fetal and perinatal life. Pediatr. Endocrinol. Rev. 17, 78–83 (2019).
pubmed: 31763800
Alidjinou, E. K., Sané, F., Engelmann, I., Geenen, V. & Hober, D. Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes. Discov. Med. 18, 273–282 (2014).
pubmed: 25425468
Bouin, A. et al. Enterovirus persistence in cardiac cells of patients with idiopathic dilated cardiomyopathy is linked to 5′ terminal genomic RNA-deleted viral populations with viral-encoded proteinase activities. Circulation 139, 2326–2338 (2019).
pubmed: 30755025
pmcid: 6517084
doi: 10.1161/CIRCULATIONAHA.118.035966
Tam, P. E. & Messner, R. P. Molecular mechanisms of coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution. J. Virol. 73, 10113–10121 (1999).
pubmed: 10559326
pmcid: 113063
doi: 10.1128/JVI.73.12.10113-10121.1999
Richardson, S. J. & Morgan, N. G. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr. Opin. Pharmacol. 43, 11–19 (2018).
pubmed: 30064099
pmcid: 6294842
doi: 10.1016/j.coph.2018.07.006
Goubau, D., Deddouche, S. & Reis e Sousa, C. Cytosolic sensing of viruses. Immunity 38, 855–869 (2013).
pubmed: 23706667
pmcid: 7111113
doi: 10.1016/j.immuni.2013.05.007
Wang, J. P. et al. MDA5 and MAVS mediate type I interferon responses to coxsackie B virus. J. Virol. 84, 254–260 (2010).
pubmed: 19846534
doi: 10.1128/JVI.00631-09
Nair, S., Leung, K. C., Rawlinson, W. D., Naing, Z. & Craig, M. E. Enterovirus infection induces cytokine and chemokine expression in insulin-producing cells. J. Med. Virol. 82, 1950–1957 (2010).
pubmed: 20872723
doi: 10.1002/jmv.21900
Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).
pubmed: 23580528
pmcid: 3704950
doi: 10.1126/science.1235208
Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211 (2013).
pubmed: 23580529
pmcid: 3640797
doi: 10.1126/science.1235214
Hall, J. C. & Rosen, A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6, 40–49 (2010).
pubmed: 20046205
pmcid: 3622245
doi: 10.1038/nrrheum.2009.237
Foulis, A. K., Farquharson, M. A. & Meager, A. Immunoreactive α-interferon in insulin-secreting β cells in type 1 diabetes mellitus. Lancet 2, 1423–1427 (1987).
pubmed: 2891993
doi: 10.1016/S0140-6736(87)91128-7
Huang, X. et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44, 658–664 (1995).
pubmed: 7540571
doi: 10.2337/diab.44.6.658
Ferreira, R. C. et al. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes 63, 2538–2550 (2014).
pubmed: 24561305
pmcid: 4066333
doi: 10.2337/db13-1777
Kallionpää, H. et al. Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 63, 2402–2414 (2014).
pubmed: 24550192
doi: 10.2337/db13-1775
Reynier, F. et al. Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. Genes Immun. 11, 269–278 (2010).
pubmed: 20090770
doi: 10.1038/gene.2009.112
Rodrigues, K. B. et al. Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes. Diabetologia 63, 1576–1587 (2020).
pubmed: 32500289
doi: 10.1007/s00125-020-05179-4
Akhbari, P., Richardson, S. J. & Morgan, N. G. Type 1 diabetes: interferons and the aftermath of pancreatic beta-cell enteroviral infection. Microorganisms 8, 1419 (2020).
pmcid: 7565444
doi: 10.3390/microorganisms8091419
Brænne, I. et al. Dynamic changes in immune gene co-expression networks predict development of type 1 diabetes. Sci. Rep. 11, 22651 (2021).
pubmed: 34811390
pmcid: 8609030
doi: 10.1038/s41598-021-01840-z
Flodström, M. et al. Target cell defense prevents the development of diabetes after viral infection. Nat. Immunol. 3, 373–382 (2002).
pubmed: 11919579
doi: 10.1038/ni771
Hultcrantz, M. et al. Interferons induce an antiviral state in human pancreatic islet cells. Virology 367, 92–101 (2007).
pubmed: 17559902
doi: 10.1016/j.virol.2007.05.010
Lombardi, A. & Tomer, Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J. Autoimmun. 80, 48–55 (2017).
pubmed: 28238527
pmcid: 5758382
doi: 10.1016/j.jaut.2017.02.002
Marroqui, L. et al. Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia 60, 656–667 (2017).
pubmed: 28062922
doi: 10.1007/s00125-016-4201-3
Colli, M. L. et al. An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells. Nat. Commun. 11, 2584 (2020).
pubmed: 32444635
pmcid: 7244579
doi: 10.1038/s41467-020-16327-0
Shimizu, F., Shimizu, M. & Kamiyama, K. Inhibitory effect of interferon on the production of insulin. Endocrinology 117, 2081–2084 (1985).
pubmed: 3899616
doi: 10.1210/endo-117-5-2081
Li, Q. et al. Interferon-α initiates type 1 diabetes in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 105, 12439–12444 (2008).
pubmed: 18716002
pmcid: 2527930
doi: 10.1073/pnas.0806439105
Foulis, A. K., Farquharson, M. A. & Hardman, R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30, 333–343 (1987).
pubmed: 3301484
pmcid: 7087521
doi: 10.1007/BF00299027
Bottazzo, G. F. et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. 313, 353–360 (1985).
pubmed: 3159965
doi: 10.1056/NEJM198508083130604
Richardson, S. J., Morgan, N. G. & Foulis, A. K. Pancreatic pathology in type 1 diabetes mellitus. Endocr. Pathol. 25, 80–92 (2014).
pubmed: 24522639
doi: 10.1007/s12022-014-9297-8
Richardson, S. J. et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59, 2448–2458 (2016).
pubmed: 27506584
pmcid: 5042874
doi: 10.1007/s00125-016-4067-4
Ylipaasto, P. et al. Global profiling of coxsackievirus- and cytokine-induced gene expression in human pancreatic islets. Diabetologia 48, 1510–1522 (2005).
pubmed: 15991020
doi: 10.1007/s00125-005-1839-7
Jonsson, A. et al. Protein kinase R is constitutively expressed in the human pancreas. J. Histochem. Cytochem. 67, 99–105 (2019).
pubmed: 30265185
doi: 10.1369/0022155418802838
Apaolaza, P. S. et al. Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. Sci. Adv. 7, eabd6527 (2021). This study showed that high expression of interferon response markers in insulin-containing islets from autoantibody-positive donors and patients with T1DM was associated with the presence of the enteroviral protein VP1 and down-regulation of several genes in the insulin secretion pathway.
pubmed: 33627420
pmcid: 7904254
doi: 10.1126/sciadv.abd6527
Chong, M. M. W., Thomas, H. E. & Kay, T. W. H. γ-interferon signaling in pancreatic β-cells is persistent but can be terminated by overexpression of suppressor of cytokine signaling-1. Diabetes 50, 2744–2751 (2001).
pubmed: 11723057
doi: 10.2337/diabetes.50.12.2744
Chong, M. M. W. et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic β cells from CD8
pubmed: 15100317
doi: 10.4049/jimmunol.172.9.5714
Barral, A. M. et al. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J. Autoimmun. 27, 166–173 (2006).
pubmed: 17045460
doi: 10.1016/j.jaut.2006.08.002
Vasu, S., McClenaghan, N. H., McCluskey, J. T. & Flatt, P. R. Mechanisms of toxicity by proinflammatory cytokines in a novel human pancreatic beta cell line, 1.1B4. Biochim. Biophys. Acta Gen. Subj. 1840, 136–145 (2014).
doi: 10.1016/j.bbagen.2013.08.022
Kay, T. W. H., Campbell, I. L., Oxbrow, L. & Harrison, L. C. Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-γ antibody. Diabetologia 34, 779–785 (1991).
pubmed: 1722764
doi: 10.1007/BF00408350
Savinov, A. Y., Wong, F. S., Stonebraker, A. C. & Chervonsky, A. V. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J. Exp. Med. 197, 643–656 (2003).
pubmed: 12615905
pmcid: 2193823
doi: 10.1084/jem.20021378
Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209, 51–60 (2012).
pubmed: 22213807
pmcid: 3260877
doi: 10.1084/jem.20111187
Lundberg, M., Krogvold, L., Kuric, E., Dahl-JØrgensen, K. & Skog, O. Expression of interferon-stimulated genes in insulitic pancreatic islets of patients recently diagnosed with type 1 diabetes. Diabetes 65, 3104–3110 (2016).
pubmed: 27422384
doi: 10.2337/db16-0616
Mathis, D., Vence, L. & Benoist, C. Beta-cell death during progression to diabetes. Nature 414, 792–798 (2001).
pubmed: 11742411
doi: 10.1038/414792a
Vives-Pi, M., Rodríguez-Fernández, S. & Pujol-Autonell, I. How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review. Apoptosis 20, 263–272 (2015).
pubmed: 25604067
pmcid: 4328127
doi: 10.1007/s10495-015-1090-8
Flodström, M., Shi, F. D., Sarvetnick, N. & Ljunggren, H. G. The natural killer cell–friend or foe in autoimmune disease? Scand. J. Immunol. 55, 432–441 (2002).
pubmed: 11975754
doi: 10.1046/j.1365-3083.2002.01084.x
Johansson, S., Berg, L., Hall, H. & Höglund, P. NK cells: elusive players in autoimmunity. Trends Immunol. 26, 613–618 (2005).
pubmed: 16118064
doi: 10.1016/j.it.2005.08.008
La Marca, V., Gianchecchi, E. & Fierabracci, A. Type 1 diabetes and its multi-factorial pathogenesis: the putative role of NK cells. Int. J. Mol. Sci. 19, 794 (2018).
pmcid: 5877655
doi: 10.3390/ijms19030794
Nekoua, M. P. et al. Enteroviral pathogenesis of type 1 diabetes: the role of natural killer cells. Microorganisms 8, 989 (2020).
pmcid: 7409131
doi: 10.3390/microorganisms8070989
Qin, H. et al. Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling. Diabetes 60, 857–866 (2011).
pubmed: 21270236
pmcid: 3046846
doi: 10.2337/db09-1706
Rodacki, M. et al. Altered natural killer cells in type 1 diabetic patients. Diabetes 56, 177–185 (2007).
pubmed: 17192480
doi: 10.2337/db06-0493
Lima, J. F., Oliveira, L. M. S., Pereira, N. Z., Duarte, A. J. S. & Sato, M. N. Polyfunctional natural killer cells with a low activation profile in response to Toll-like receptor 3 activation in HIV-1-exposed seronegative subjects. Sci. Rep. 7, 524 (2017).
pubmed: 28373665
pmcid: 5428831
doi: 10.1038/s41598-017-00637-3
Blanter, M., Sork, H., Tuomela, S. & Flodström-Tullberg, M. Genetic and environmental interaction in type 1 diabetes: a relationship between genetic risk alleles and molecular traits of enterovirus infection? Curr. Diab. Rep. 19, 82 (2019).
pubmed: 31401790
pmcid: 6689284
doi: 10.1007/s11892-019-1192-8
Chehadeh, W., Bouzidi, A., Alm, G., Wattré, P. & Hober, D. Human antibodies isolated from plasma by affinity chromatography increase the coxsackievirus B4-induced synthesis of interferon-α by human peripheral blood mononuclear cells in vitro. J. Gen. Virol. 82, 1899–1907 (2001).
pubmed: 11457996
doi: 10.1099/0022-1317-82-8-1899
Hober, D. et al. Circulating and cell-bound antibodies increase coxsackievirus B4-induced production of IFN-α by peripheral blood mononuclear cells from patients with type 1 diabetes. J. Gen. Virol. 83, 2169–2176 (2002).
pubmed: 12185270
doi: 10.1099/0022-1317-83-9-2169
Chehadeh, W. et al. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. J. Virol. 79, 13882–13891 (2005).
pubmed: 16254324
pmcid: 1280186
doi: 10.1128/JVI.79.22.13882-13891.2005
Alidjinou, E. K., Sané, F., Engelmann, I. & Hober, D. Serum-dependent enhancement of coxsackievirus B4-induced production of IFNα, IL-6 and TNFα by peripheral blood mononuclear cells. J. Mol. Biol. 425, 5020–5031 (2013).
pubmed: 24120940
doi: 10.1016/j.jmb.2013.10.008
Benkahla, M. A. et al. Coxsackievirus-B4E2 can infect monocytes and macrophages in vitro and in vivo. Virology 522, 271–280 (2018).
pubmed: 30056354
doi: 10.1016/j.virol.2018.06.010
Hober, D., Chehadeh, W., Bouzidi, A. & Wattré, P. Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-α synthesis. J. Infect. Dis. 184, 1098–1108 (2001).
pubmed: 11598831
doi: 10.1086/323801
Alidjinou, E. K., Sané, F., Trauet, J., Copin, M. C. & Hober, D. Coxsackievirus B4 can infect human peripheral blood-derived macrophages. Viruses 7, 6067–6079 (2015).
pubmed: 26610550
pmcid: 4664995
doi: 10.3390/v7112924
Sane, F. et al. Enhancing and neutralizing anti-coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes. Diabetes Metab. Res. Rev. 36, e3305 (2020). In this prospective study, the enhancing activity of anti-coxsackievirus antibodies was predominant or even exclusive over their neutralizing activity, in consecutive serum samples from children prior to development of T1DM.
pubmed: 32118346
doi: 10.1002/dmrr.3305
Elmastour, F. et al. Immunoglobulin G-dependent enhancement of the infection with coxsackievirus B4 in a murine system. Virulence 7, 527–535 (2016).
pubmed: 27030584
pmcid: 5026789
doi: 10.1080/21505594.2016.1152442
Elmastour, F. et al. Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4. Virulence 8, 908–923 (2017).
pubmed: 27792461
doi: 10.1080/21505594.2016.1252018
Grandi, N. & Tramontano, E. HERV envelope proteins: physiological role and pathogenic potential in cancer and autoimmunity. Front. Microbiol. 9, 462 (2018).
pubmed: 29593697
pmcid: 5861771
doi: 10.3389/fmicb.2018.00462
Levet, S. et al. An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes. JCI Insight 2, e94387 (2017).
pmcid: 5621895
doi: 10.1172/jci.insight.94387
Levet, S. et al. Human endogenous retroviruses and type 1 diabetes. Curr. Diab. Rep. 19, 141 (2019).
pubmed: 31754894
pmcid: 6872510
doi: 10.1007/s11892-019-1256-9
Dechaumes, A. et al. Coxsackievirus-B4 infection can induce the expression of human endogenous retrovirus W in primary cells. Microorganisms 8, 1335 (2020).
pmcid: 7563422
doi: 10.3390/microorganisms8091335
Lafon, M., Jouvin-Marche, E., Marche, P. N., Perron, H. & Woodland, D. L. Human viral superantigens: to be or not to be transactivated? Trends Immunol. 23, 238–239 (2002).
pubmed: 12102742
doi: 10.1016/S1471-4906(02)02207-X
Zhu, F. et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370, 818–828 (2014).
pubmed: 24571754
doi: 10.1056/NEJMoa1304923
Okayasu, H., Sein, C., Hamidi, A., Bakker, W. A. M. & Sutter, R. W. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals 44, 581–587 (2016).
pubmed: 27720268
doi: 10.1016/j.biologicals.2016.08.005
Hu, Y. et al. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum. Vaccin. Immunother. 14, 1517–1523 (2018).
pubmed: 29482422
pmcid: 6037439
doi: 10.1080/21645515.2018.1442997
Tambyah, P. A. et al. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: a phase I, double blind, randomized, placebo-controlled, study of two dosages. Vaccine 37, 4344–4353 (2019).
pubmed: 31230881
doi: 10.1016/j.vaccine.2019.06.023
Soriano, V. et al. Hepatitis C cure with antiviral therapy–benefits beyond the liver. Antivir. Ther. 21, 1–8 (2016).
pubmed: 26110692
doi: 10.3851/IMP2975
Okada, M., Enomoto, M., Kawada, N. & Nguyen, M. H. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert. Rev. Gastroenterol. Hepatol. 11, 1095–1104 (2017).
pubmed: 28752768
doi: 10.1080/17474124.2017.1361822
Larsson, P. G. et al. A preclinical study on the efficacy and safety of a new vaccine against coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia 58, 346–354 (2015).
pubmed: 25370797
doi: 10.1007/s00125-014-3436-0
Stone, V. M. et al. A coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia 61, 476–481 (2018).
pubmed: 29151123
doi: 10.1007/s00125-017-4492-z
Hober, D. & Alidjinou, E. K. Diabetes: towards a coxsackievirus B-based vaccine to combat T1DM. Nat. Rev. Endocrinol. 14, 131–132 (2018).
pubmed: 29327705
doi: 10.1038/nrendo.2017.184
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04690426 (2022).
Stone, V. M. et al. A hexavalent coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci. Adv. 6, eaaz2433 (2020). This preclinical study demonstrated that a high immunogenic hexavalent CVB vaccine is capable of preventing CVB-induced diabetes mellitus in mice, providing proof-of-concept for further studies in humans.
pubmed: 32494709
pmcid: 7202868
doi: 10.1126/sciadv.aaz2433
Koho, T. et al. Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice. Antivir. Res. 104, 93–101 (2014).
pubmed: 24485896
doi: 10.1016/j.antiviral.2014.01.013
Hankaniemi, M. M. et al. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antivir. Res. 171, 104595 (2019).
pubmed: 31491431
doi: 10.1016/j.antiviral.2019.104595
Hankaniemi, M. M. et al. Structural insight into CVB3-VLP non-adjuvanted vaccine. Microorganisms 8, 1287 (2020).
pmcid: 7565060
doi: 10.3390/microorganisms8091287
Hassine, I. H. et al. Characterization of coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein. Mol. Biol. Rep. 47, 2835–2843 (2020).
pubmed: 32240468
doi: 10.1007/s11033-020-05333-6
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04838145 (2021).
Sioofy-Khojine, A. B., Honkimaa, A. & Hyöty, H. A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Diabet. Med. 37, 1849–1853 (2020).
pubmed: 31705692
doi: 10.1111/dme.14175
Andries, K. et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 36, 100–107 (1992).
pubmed: 1317142
pmcid: 189235
doi: 10.1128/AAC.36.1.100
Vance, L. M., Moscufo, N., Chow, M. & Heinz, B. A. Poliovirus 2C region functions during encapsidation of viral RNA. J. Virol. 71, 8759–8765 (1997).
pubmed: 9343235
pmcid: 192341
doi: 10.1128/jvi.71.11.8759-8765.1997
Klein, M., Hadaschik, D., Zimmermann, H., Eggers, H. J. & Nelsen-Salz, B. Picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C. J. Gen. Virol. 81, 895–901 (2000).
pubmed: 10725414
doi: 10.1099/0022-1317-81-4-895
Verlinden, Y., Cuconati, A., Wimmer, E. & Rombaut, B. The antiviral compound 5-(3,4-dichlorophenyl) methylhydantoin inhibits the post-synthetic cleavages and the assembly of poliovirus in a cell-free system. Antivir. Res. 48, 61–69 (2000).
pubmed: 11080541
doi: 10.1016/S0166-3542(00)00119-4
Kearns, G. L. et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatr. Infect. Dis. J. 19, 833–839 (2000).
pubmed: 11001105
doi: 10.1097/00006454-200009000-00005
Aradottir, E., Alonso, E. M. & Shulman, S. T. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr. Infect. Dis. J. 20, 457–459 (2001).
pubmed: 11332680
doi: 10.1097/00006454-200104000-00022
Zuo, J. et al. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob. Agents Chemother. 56, 4838–4844 (2012).
pubmed: 22751539
pmcid: 3421851
doi: 10.1128/AAC.00983-12
Nekoua, M. P. et al. Fighting enteroviral infections to prevent type 1 diabetes. Microorganisms 10, 768 (2022).
pubmed: 35456818
pmcid: 9031364
doi: 10.3390/microorganisms10040768
Alidjinou, E. K., Sané, F., Bertin, A., Caloone, D. & Hober, D. Persistent infection of human pancreatic cells with coxsackievirus B4 is cured by fluoxetine. Antivir. Res. 116, 51–54 (2015).
pubmed: 25655448
doi: 10.1016/j.antiviral.2015.01.010
Benkahla, M. A., Alidjinou, E. K., Sane, F., Desailloud, R. & Hober, D. Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo. Antivir. Res. 159, 130–133 (2018).
pubmed: 30290197
doi: 10.1016/j.antiviral.2018.10.002
Honkimaa, A. et al. Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs. J. Clin. Virol. 128, 104334 (2020).
pubmed: 32450550
doi: 10.1016/j.jcv.2020.104334
Alidjinou, E. K. et al. Emergence of fluoxetine-resistant variants during treatment of human pancreatic cell cultures persistently infected with coxsackievirus B4. Viruses 11, 486 (2019).
pmcid: 6630805
doi: 10.3390/v11060486
Lin, H. et al. Efficacy of Scutellaria baicalensis for the treatment of hand, foot, and mouth disease associated with encephalitis in patients infected with EV71: a multicenter, retrospective analysis. Biomed. Res. Int. 2016, 5697571 (2016).
pubmed: 27840828
pmcid: 5093290
doi: 10.1155/2016/5697571
El Kfoury, K. A. et al. Bifidobacteria-derived lipoproteins inhibit infection with coxsackievirus B4 in vitro. Int. J. Antimicrob. Agents 50, 177–185 (2017).
pubmed: 28595938
doi: 10.1016/j.ijantimicag.2017.03.010
Arena, M. P. et al. Inhibition of coxsackievirus B4 by Lactobacillus plantarum. Microbiol. Res. 210, 59–64 (2018).
pubmed: 29625659
doi: 10.1016/j.micres.2018.03.008
Badia-Boungou, F. et al. Aqueous extracts of Syzygium brazzavillense can inhibit the infection with coxsackievirus B4 in vitro. J. Med. Virol. 91, 1210–1216 (2019).
pubmed: 30788849
doi: 10.1002/jmv.25436
Taylor, P. C. et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann. Rheum. Dis. 81, 335–343 (2022).
pubmed: 34706874
doi: 10.1136/annrheumdis-2021-221276
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04774224 (2021).
Guo, H. et al. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nat. Commun. 10, 4066 (2019).
pubmed: 31492846
pmcid: 6731315
doi: 10.1038/s41467-019-12040-9
Lulla, V. et al. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells. Nat. Microbiol. 4, 280–292 (2019).
pubmed: 30478287
doi: 10.1038/s41564-018-0297-1